FDA accepts Ionis olezarsen application for priority review
Tweet Send to a Friend
The U.S. Food and Drug Administration has accepted Ionis Pharmaceuticals Inc.'s (NASDAQ: IONS) supplemental new drug application for olezarsen to ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


